Steven Berthel

Title: Steven Berthel: Innovator in Biotechnology

Introduction

Steven Berthel is a notable inventor based in Mendham, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target Bruton's tyrosine kinase (Btk). His work is essential for advancing treatments for various diseases.

Latest Patents

Steven Berthel holds a patent for "Inhibitors of Bruton's tyrosine kinase." This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formula I-III. The variables Q, R, X, X', Y, m, and n are defined as described in the patent. These compounds inhibit Btk and are useful for modulating its activity to treat diseases associated with excessive Btk activity. Additionally, they are beneficial in treating inflammatory and autoimmune diseases linked to aberrant B-cell proliferation, such as rheumatoid arthritis. The patent also includes compositions containing these compounds and at least one carrier, diluent, or excipient.

Career Highlights

Steven Berthel is currently associated with Roche Palo Alto LLC, where he continues to innovate in the field of biotechnology. His work has the potential to impact the treatment landscape for various diseases significantly.

Collaborations

Steven collaborates with notable colleagues, including Fariborz Firooznia and Daniel Fishlock. Their combined expertise enhances the research and development efforts at Roche Palo Alto LLC.

Conclusion

Steven Berthel's contributions to biotechnology, particularly through his patent on Btk inhibitors, showcase his commitment to advancing medical treatments. His work is vital for addressing complex diseases and improving patient outcomes.